

Central Zone

Pathology and Laboratory Medicine Memorandum

To:	Provincial Oncology Group
From:	Dr. Wenda Greer, Clinical Director of Molecular Diagnostics
	Randy Veinotte, Esoteric Laboratory Manager
Date:	December 18, 2020
Subject:	Circulating Tumor DNA Testing

The Molecular Diagnostics laboratory is now offering a new test, Circulating Tumor EGRF, to detect sensitizing (EGFR L858R and EGFR exon 19del) and resistance (EGFR T790M) EGFR mutations in circulating tumor DNA in lung cancer patients. The detection of these mutations in blood plasma might allow the patient to move to second line therapy without the need for a second biopsy at relapse.

To ensure appropriate utilization the requesting of this test will be restricted to oncologists.

The test must be ordered using the molecular requisition (Req #CD2573) and select "Circulating Tumor EGFR". Please include the patient's sensitizing EGFR mutation.

If you have any questions please contact Dr. Wenda Greer at 902-473-6691 (wenda.greer@nshealth.ca) or the Molecular Diagnostic laboratory at 902-473-6665.